Helen Torley, PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC. (HALO), sold 50,000 shares at $66.39 ($3.4M) on 2026-06-01, disclosed to the SEC on 2026-06-03.
Scheduled sale ($3.4M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $66.39 | 1,610 | $107K | 3.2% |
| 2 | $67.41 | 12,989 | $876K | 26.0% |
| 3 | $68.35 | 5,401 | $369K | 11.0% |
| 4 | $66.31 | 16,600 | $1.1M | 32.7% |
| 5 | $66.75 | 3,400 | $227K | 6.7% |
| 6 | $66.37 | 400 |
| $27K |
| 0.8% |
| 7 | $67.67 | 1,500 | $102K | 3.0% |
| 8 | $68.74 | 2,000 | $137K | 4.1% |
| 9 | $69.69 | 6,100 | $425K | 12.6% |
| Total | $67.40 avg | 50,000 | $3.4M | 100% |
| Filing → |
| HALO | SELL | 2026-07-09 | $153K | — | Filing → |
| HALO | SELL | 2026-05-13 | $3.4M | — | Filing → |
| HALO | SELL | 2026-04-07 | $635K | — | Filing → |